key: cord-1033273-k8a6gqvn authors: Kishimoto, T.; Kinoshita, S.; Bun, S.; Sato, Y.; Kitazawa, M.; Kikuchi, T.; Sado, M.; Takamiya, A.; Mimura, M.; Nakamae, T.; Abe, Y.; Kanazawa, T.; Kawabata, Y.; Tomita, H.; Abe, K.; Hishimoto, A.; Asami, T.; Suda, A.; Watanabe, Y.; Amagai, T.; Sakuma, K.; Kida, H.; Funayama, M.; Kimura, H.; Sato, A.; Fujiwara, S.; Nagao, K.; Sugiyama, N.; Takamiya, M.; Kodama, H.; Azekawa, T. title: Japanese Project for Telepsychiatry Evaluation during COVID-19: Treatment Comparison Trial (J-PROTECT): Rationale, design, and methodology date: 2021-06-29 journal: nan DOI: 10.1101/2021.06.23.21259366 sha: 95dc0d4fc0a72159345c319de183ed1777a8c53f doc_id: 1033273 cord_uid: k8a6gqvn Introduction: The COVID-19 pandemic has had a profound impact on the mental health of people around the world. Anxiety related to infection, stress and stigma caused by the forced changes in daily life have reportedly increased the incidence and symptoms of depression, anxiety disorder and obsessive-compulsive disorder. Under such circumstances, telepsychiatry is gaining importance and attracting a great deal of attention. However, few large pragmatic clinical trials on the use of telepsychiatry targeting multiple psychiatric disorders have been conducted to date. Methods: The targeted study cohort will consist of adults (>18 years) who meet the DSM-5 diagnostic criteria for either (1) depressive disorders, (2) anxiety disorders, or (3) obsessive-compulsive and related disorders. Patients will be assigned in a 1:1 ratio to either a telepsychiatry group (at least 50% of visits to be conducted using telemedicine, with at least one face-to-face treatment [FTF] every six months) or an FTF group (all visits to be conducted FTF, with no telemedicine). Both groups will receive the usual treatment covered by public medical insurance. The study will utilize a master protocol design in that there will be primary and secondary outcomes for the entire group regardless of diagnosis, as well as the outcomes for each individual disorder group. Discussion: This study will be a non-inferiority trial to test that the treatment effect of telepsychiatry is not inferior to that of FTF alone. This study will provide useful insights into the effect of the COVID-19 pandemic on the practice of psychiatry. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 29, 2021. ; https://doi.org/10.1101/2021.06.23.21259366 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 29, 2021. ; https://doi.org/10.1101/2021.06.23.21259366 doi: medRxiv preprint 5 using telemedicine, with at least one face-to-face treatment [FTF] every six months) or an "FTF group" (all 71 visits to be conducted FTF, with no telemedicine). Both groups will receive the usual treatment covered by 72 public medical insurance. The study will utilize a master protocol design in that there will be primary and 73 secondary outcomes for the entire group regardless of diagnosis, as well as the outcomes for each individual 74 disorder group. Discussion: This study will be a non-inferiority trial to test that the treatment effect of telepsychiatry is not 76 inferior to that of FTF alone. This study will provide useful insights into the effect of the COVID-19 pandemic 77 on the practice of psychiatry. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 29, 2021. ; https://doi.org/10.1101/2021.06.23.21259366 doi: medRxiv preprint The 2019 novel coronavirus disease (COVID-19) pandemic, which is raging worldwide, has had significant 94 direct and indirect impacts on mental health. The incidence of symptoms, such as anxiety, depression, and 95 obsessive-compulsive disorder (OCD), in the general population is reportedly higher than during pre-pandemic 96 times as a result of the effects of lockdowns and other restrictions on going out, sudden unemployment, and 97 frequent exposure to related topics through news associated with the COVID-19 pandemic [1] [2] . People 98 infected with COVID-19 also reportedly have a higher risk of developing psychiatric disorders, and people with 99 a history of psychiatric disorders have a higher diagnosis rate of COVID-19 infection [3] . This situation suggests 100 that psychiatric care is becoming increasingly important under the COVID-19 pandemic. However, during the COVID-19 pandemic, patients may refrain from visiting hospitals because of fears of 102 infection, and hospitals may stop performing outpatient consultations. According to a survey conducted by 103 WHO in 130 countries, 93% of the countries surveyed reported obstacles to providing psychiatric and mental 104 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted June 29, 2021. ; https://doi.org/10.1101/2021.06.23.21259366 doi: medRxiv preprint health services [4] . Under these circumstances, it is important to find ways to continue the provision of 105 psychiatric care. In past epidemics of infectious diseases, telemedicine has been used to prevent infection among 106 healthcare workers by using the telephone and video calls to conduct consultations [5] . During the recent 107 pandemic, telemedicine has attracted attention as a way of continuing medical care while preventing infection, 108 and its use has rapidly expanded due to deregulation in many countries [6]. In psychiatry, outpatient care is mainly conducted in the form of in-person conversations; therefore, doctor- As COVID-19 is expected to take some time to fully resolve, verifying whether telemedicine is as effective 119 as FTF treatment in real-world clinical practice for the treatment of depression, anxiety, and OCD in existing 120 clinical settings is of great importance, particularly since increases in the diagnosis or exacerbation of these 121 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) Patients will be assigned in a 1:1 ratio to either a "telepsychiatry group" (at least 50% of visits to be 126 conducted by telemedicine, with at least one FTF every six months) or an "FTF group" (all visits to be FTF, 127 with no telemedicine). Both groups will receive the usual treatment covered by public medical insurance. The interval between visits will be at the discretion of the psychiatrist in charge. This study will have a master 129 protocol with primary and secondary outcomes for the entire group as well as outcomes for each individual 130 disorder group. The main objective of this study will be to show that the telepsychiatry group is non-inferior to the FTF 132 group after 6 months of practice in patients with depressive disorder, anxiety disorder, or OCD and related 133 disorders. This study will be a multi-site, prospective randomized controlled trial. Participants will be recruited at 17 136 medical institutions that provide psychiatric services in 11 different prefectures in Japan. Patient recruitment 137 will be conducted at the following locations and medical institutions: Tokyo (Keio University Hospital, . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The inclusion criteria for participants will be as follows: 1) patients who meet the Diagnostic and Statistical CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 29, 2021. ; https://doi.org/10.1101/2021.06.23.21259366 doi: medRxiv preprint urgent visits to the hospital in addition to regular visits because of emergent suicidal ideation, anxiety or 156 agitation; and 2) patients who have difficulty managing an emergency visit by themselves when their psychiatric 157 conditions deteriorate (e.g., the hospital is located far away). Researchers will obtain written informed consent 158 from all the participants. The participants will be able to leave the study at any time. Patients who have given their consent to participate in this study will be randomly assigned in a 1:1 ratio to 161 the "Telepsychiatry group" or the "FTF group" for treatment during the study period. In this study, to avoid 162 inter-institutional differences and biases in the types of disorders among the groups, randomization process is 163 carried out by a blinded, independent third party using a modified minimization method with a biased-coin 164 assignment balanced for age group (60 years old or older, or younger), gender (male or female), target disorder, 165 and participating institution. In addition, the allocation results will not be disclosed to the central evaluator to The assessment schedule is presented in Table 1 . After randomization, participants will be assessed with the 169 SF36MCS at baseline and at weeks 12 and 24. The duration of each patient's participation in the study is 170 estimated to be approximately 6 to 7 months, including the allowance period for the prescribed visits. The primary outcome of the study is health-related quality of life as assessed using the SF36MCS, which 189 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. In the present study, assuming that the SF36MCS of the telemedicine and FTF groups at 6 months is 45 (no In this study, the dropout rate is expected to be low because the primary psychiatrist who have been treating COVID-19 will be collected as self-administered patient-reported outcome measures. We will construct and 204 operate a system to store these data directly using electronic data capture (EDC) and an electronic patient-205 reported outcome (ePRO). We will use "cubeCDMS" by CRScube Inc. for EDC and "cubePro" by CRScube . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 29, 2021. ; https://doi.org/10.1101/2021.06.23.21259366 doi: medRxiv preprint 13 Inc. for ePRO. The participants will install the ePRO application on their smartphones, etc., access the 207 questionnaire included in the application, and enter and transmit the data. For the HAMD, HAMA, and YBOCS, 208 remote centralized ratings performed through a video camera feed will be used. Evaluators must have completed 209 a total of at least 30 hours of training on these evaluation items, and the evaluator will assess the examinees 210 through a video camera feed at the time of each visit. In addition, as an optional part of the study, both FTF 211 evaluations and centralized ratings for HAMD, HAMA, and YBOCS will be performed for patients who are 212 willing to participate, so as to validate the centralized ratings. For the primary analysis, aimed at comparing treatment effects, the least square mean and its 95% confidence 221 interval (CI) will be estimated using a mixed-effects model for repeated measurements (MMRM). No 222 imputation of missing data was performed. The MMRM model will include treatment, visit, treatment-by-visit 223 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The secondary analysis will be performed in the same manner as the primary analysis. All comparisons are 229 planned and all p values will be two sided. P values < 0.05 will be considered statistically significant. All The J-PROTECT study is an important study in both the psychiatric and telemedicine fields, as the COVID-239 19 outbreak is far from under control. The wide practice of telemedicine in this field is meaningful as an effective 240 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 29, 2021. ; https://doi.org/10.1101/2021.06.23.21259366 doi: medRxiv preprint countermeasure against infection and to prove that telepsychiatry is effective for the treatment of psychiatric 241 disorders that can worsen during a pandemic. As mentioned above, many studies comparing telepsychiatry with 242 FTF treatment have focused on specific disorders or specific treatments, such as CBT, but few studies have The novelty of the present study is that it will be the first pragmatic trial of telepsychiatry in Japan, a country 249 that provides universal health insurance that allows free access to medical services with relatively low cost. It 250 will also be a multi-center, multi-regional study, unlike previous pragmatic trials of multiple psychiatric 251 disorders. Since the degree and content of telepsychiatry regulation varies in each country [6] , showing that 252 telepsychiatry is equally effective in different regulatory and cultural settings will be important to promote its 253 use appropriately. In considering the study design, several issues needed to be taken into account. First, the rationale for 255 selecting SF36MCS as the primary outcome in this study was that it was necessary to establish an outcome that 256 encompassed depressive disorder, anxiety disorder, and OCD and related disorders and that was in use at many 257 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 29, 2021. ; https://doi.org/10.1101/2021.06.23.21259366 doi: medRxiv preprint psychiatric clinical studies as a health-related quality of life (QOL), which is a superordinate concept for the 258 severity of all illnesses [11] [12] [13] [14] [15] [16] . Next, the reason why we set the percentage of telemedicine in the telepsychiatry 259 group to be more than 50% is to allow room for the use of both FTF and telepsychiatry depending on the patient's 260 condition, just as in regular medical care. The Japanese government guidelines also do not recommend the 261 continuation of long-term treatment with telemedicine alone [19] . The limitations of this study are as follows. First, we targeted three disorder groups, namely depressive 263 disorders, anxiety disorders, and OCD and related disorders. In addition to targeting three disorders in one trial, 264 the demographic characteristics of the participants may vary over a wide range. This may lead to difficulty in 265 finding a comparative effect size of telemedicine; however, this is an inherent difficulty of pragmatic trials, and 266 limiting participation to a specific patient population may limit the generalizability of the results. Related to this 267 point, IT literacy might be the largest modulator of the results, and since Japan is a world-leading aging society, 268 this fact is of particular consideration. Elderly people generally experience more hurdles to telemedicine because 269 of IT literacy issues [20] . By randomizing the whole population, we reduce the risk of the impact of this possible 270 modulator. At the same time, by asking the participants regarding their impressions or hurdles regarding 271 telemedicine utilization in a free-answer format, we hope to gather information that will enable us to help elderly 272 or low-IT literacy patients to take advantage of telemedicine in the future. Finally, the implementation of this 273 study may be affected by the status of the COVID-19 pandemic. If the pandemic becomes serious, there is a 274 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 29, 2021. ; https://doi.org/10.1101/2021.06.23.21259366 doi: medRxiv preprint risk that hospitals will suspend FTF treatment or that patients will refuse to come to the hospital for fear of the 275 risk of infection. In any case, we will implement an appropriate combination of telepsychiatry and FTF treatment, All authors critically revised the manuscript, and approved the manuscript to be published, and agree to be 308 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Impact of COVID-19 pandemic on mental health in the general population: A systematic review Obsessive-compulsive disorder during COVID-19: Turning 332 a problem into an opportunity? Bidirectional associations between COVID-19 and 334 psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA World Health Organization. The impact of COVID-19 on mental, neurological and substance use services: 337 results of a rapid assessment Role of Telehealth in the Management of COVID Lessons Learned from Previous SARS, MERS, and Ebola Outbreaks Practice-based versus telemedicine-based collaborative care for depression in rural 360 federally qualified health centers: a pragmatic randomized comparative effectiveness trial Comparative Effectiveness of Cognitive Therapy and Dynamic Psychotherapy for Major 364 Depressive Disorder in a Community Mental Health Setting: A Randomized Clinical Noninferiority Trial Erratum in: JAMA 366 Psychiatry Effects of continuation electroconvulsive therapy on 370 quality of life in elderly depressed patients: A randomized clinical trial Low-intensity cognitive-behaviour therapy interventions 375 for obsessive-compulsive disorder compared to waiting list for therapist-led cognitive-behaviour therapy: 3-376 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity arm randomised controlled trial of clinical effectiveness Delivered Stepped Collaborative Care for Treating Anxiety in Primary Care: A Randomized Controlled Trial Effectiveness of cognitive-behavioral therapy on quality of life, anxiety, and depressive symptoms among 384 patients with inflammatory bowel disease: A multicenter randomized controlled trial Is telepsychiatry equivalent to 387 face-to-face psychiatry? Results from a randomized controlled equivalence trial Randomized clinical trial of 390 telepsychiatry through videoconference versus face-to-face conventional psychiatric treatment . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted June 29, 2021. After obtaining consent, patients will be assigned to either the FTF group or the Telepsychiatry group, and they will continue to receive treatment for 6 months.(The interval between visits will be determined by the attending physician.) ☆ : For each disorder group, outcomes unique to each disorder will be 405 investigated. A centralized evaluation system will be adopted in which 406 patients and evaluators will be connected remotely. For patients with partial 407 cooperation, both face-to-face evaluation and telemedicine with central 408 evaluation will be conducted for the purpose of verifying the reliability of 409 the outcomes of each disorder group. 410 411 . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted June 29, 2021. ; https://doi.org/10.1101/2021.06.23.21259366 doi: medRxiv preprint